Literaturverzeichnis

[1] Cervera, R. und Shoenfeld, Y. (2007): Pathogenic mechanisms and clinical relevance of autoantibodies, Shoenfeld, Y.; Gershwin, M. E. und Meroni, P. L., Autoantibodies , 2. Auflage, Seite 29-35, Elsevier Academic Press,

[2] Oertelt, S.; Invernizzi, P.; Podda, M. und Gershwin, M. E. (2007): What is an autoantibody?, Shoenfeld, Y.; Gershwin, M. E. und Meroni, P. L., Autoantibodies , 2. Auflage, Seite 3-6, Elsevier Academic Press,

[3] Amital, H. und Shoenfeld, Y. (2007): Natural autoantibodies, heralding, protecting and inducing autoimmunity, Shoenfeld, Y.; Gershwin, M. E. und Meroni, P. L., Autoantibodies , 2. Auflage, Seite 7-12, Elsevier Academic Press,

[4] Avrameas, S. und Ternynck, T. (1993): The natural autoantibodies system: between hypotheses and facts, Mol.Immunol. (Band 30), Nr. 12, Seite 1133-1142. URL:

[5] Kohler, H.; Bayry, J.; Nicoletti, A. und Kaveri, S. V. (2003): Natural autoantibodies as tools to predict the outcome of immune response?, Scand.J.Immunol. (Band 58), Nr. 3, Seite 285-289. URL:

[6] Cohen, I. R. (2000): Discrimination and dialogue in the immune system, Semin.Immunol. (Band 12), Nr. 3, Seite 215-219. URL:

[7] Gorsuch, A. N.; Spencer, K. M.; Lister, J.; McNally, J. M.; Dean, B. M.; Bottazzo, G. F. und Cudworth, A. G. (1981): Evidence for a long prediabetic period in type I (insulin-dependent) diabetes mellitus, Lancet (Band 2), Nr. 8260-61, Seite 1363-1365. URL:

[8] Harel, M. und Shoenfeld, Y. (2006): Predicting and preventing autoimmunity, myth or reality?, Ann.N.Y.Acad.Sci. (Band 1069), Seite 322-345. URL:

[9] Arbuckle, M. R.; McClain, M. T.; Rubertone, M. V.; Scofield, R. H.; Dennis, G. J.; James, J. A. und Harley, J. B. (2003): Development of autoantibodies before the clinical onset of systemic lupus erythematosus, N.Engl.J.Med. (Band 349), Nr. 16, Seite 1526-1533. URL:

[10] Dechend, R.; Gratze, P.; Wallukat, G.; Shagdarsuren, E.; Plehm, R.; Bräsen, J. H.; Fiebeler, A.; Schneider, W.; Caluwaerts, S.; Vercruysse, L.; Pijnenborg, R.; Luft, F. C. und Müller, D. N. (2005): Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia, Hypertension (Band 45), Nr. 4, Seite 742-746. URL:

[11] Dechend, R.; Homuth, V.; Wallukat, G.; Kreuzer, J.; Park, J. K.; Theuer, J.; Juepner, A.; Gulba, D. C.; Mackman, N.; Haller, H. und Luft, F. C. (2000): AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor, Circulation (Band 101), Nr. 20, Seite 2382-2387. URL:

[12] Wallukat, G.; Morwinski, M.; Kowal, K.; Förster, A.; Boewer, V. und Wollenberger, A. (1991): Autoantibodies against the beta-adrenergic receptor in human myocarditis and dilated cardiomyopathy: beta-adrenergic agonism without desensitization, Eur.Heart J. (Band 12 Suppl D), Seite 178-181. URL:

[13] Wallukat, G. und Wollenberger, A. (1991): Autoantibodies to beta 2-adrenergic receptors with antiadrenergic activity from patients with allergic asthma, J.Allergy Clin.Immunol. (Band 88), Nr. 4, Seite 581-587. URL:

[14] Fu, M. L.; Herlitz, H.; Wallukat, G.; Hilme, E.; Hedner, T.; Hoebeke, J. und Hjalmarson, A. (1994): Functional autoimmune epitope on alpha 1-adrenergic receptors in patients with malignant hypertension, Lancet (Band 344), Nr. 8938, Seite 1660-1663. URL:

[15] Dörffel, W. V.; Felix, S. B.; Wallukat, G.; Brehme, S.; Bestvater, K.; Hofmann, T.; Kleber, F. X.; Baumann, G. und Reinke, P. (1997): Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy, Circulation (Band 95), Nr. 8, Seite 1994-1997. URL:

[16] Felix, S. B.; Staudt, A.; Dörffel, W. V.; Stangl, V.; Merkel, K.; Pohl, M.; Docke, W. D.; Morgera, S.; Neumayer, H. H.; Wernecke, K. D.; Wallukat, G.; Stangl, K. und Baumann, G. (2000): Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study, J.Am.Coll.Cardiol. (Band 35), Nr. 6, Seite 1590-1598. URL:

[17] Müller, J.; Wallukat, G.; Dandel, M.; Bieda, H.; Brandes, K.; Spiegelsberger, S.; Nissen, E.; Kunze, R. und Hetzer, R. (2000): Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy, Circulation (Band 101), Nr. 4, Seite 385-391. URL:

[18] Dragun, D.; Müller, D. N.; Bräsen, J. H.; Fritsche, L.; Nieminen-Kelhä, M.; Dechend, R.; Kintscher, U.; Rudolph, B.; Hoebeke, J.; Eckert, D.; Mazak, I.; Plehm, R.; Schönemann, C.; Unger, T.; Budde, K.; Neumayer, H. H.; Luft, F. C. und Wallukat, G. (2005): Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection, N.Engl.J.Med. (Band 352), Nr. 6, Seite 558-569.

[19] Wallukat, G.; Nissen, E.; Müller, J.; Brinckmann, R.; Schimke, I. und Kunze, R. (2002): The pathophysiological role of autoantibodies directed to G-protein coupled receptors and therapeutic strategies of antibody removal, Conrad, K.; Fritzler, M.; Meurer, M.; Sack, U. und Shoenfeld, Y., From proteomics to molecular epidemiology: Relevance of autoantibodies. Report on the 6th Symposium on Autoantibodies , Seite 332-372,

[20] Luther, H. P.; Homuth, V. und Wallukat, G. (1997): Alpha 1-adrenergic receptor antibodies in patients with primary hypertension, Hypertension (Band 29), Nr. 2, Seite 678-682. URL:

[21] Wallukat, G.; Nissen, E.; Morwinski, R. und Müller, J. (2000): Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy, Herz. (Band 25), Nr. 3, Seite 261-266.

[22] Elies, R.; Ferrari, I.; Wallukat, G.; Lebesgue, D.; Chiale, P.; Elizari, M.; Rosenbaum, M.; Hoebeke, J. und Levin, M. J. (1996): Structural and functional analysis of the B cell epitopes recognized by anti-receptor autoantibodies in patients with Chagas' disease, J.Immunol. (Band 157), Nr. 9, Seite 4203-4211. URL:

[23] Sterin-Borda, L.; Perez, Leiros C.; Wald, M.; Cremaschi, G. und Borda, E. (1988): Antibodies to beta 1 and beta 2 adrenoreceptors in Chagas' disease, Clin.Exp.Immunol. (Band 74), Nr. 3, Seite 349-354.

[24] Wallukat, G. und Wollenberger, A. (1987): Effects of the serum gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic beta adrenoceptor function in cultured neonatal rat heart myocytes, Biomed.Biochim.Acta. (Band 46), Nr. 8-9, Seite S634-S639.

[25] Wallukat, G.; Homuth, V.; Fischer, T.; Lindschau, C.; Horstkamp, B.; Jupner, A.; Baur, E.; Nissen, E.; Vetter, K.; Neichel, D.; Dudenhausen, J. W.; Haller, H. und Luft, F. C. (1999): Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor, J.Clin.Invest. (Band 103), Nr. 7, Seite 945-952.

[26] Fu, M. L.; Herlitz, H.; Schulze, W.; Wallukat, G.; Micke, P.; Eftekhari, P.; Sjogren, K. G.; Hjalmarson, A.; Muller-Esterl, W. und Hoebeke, J. (2000): Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension, J.Hypertens. (Band 18), Nr. 7, Seite 945-953. URL:

[27] Dragun, D; Wallukat, G.; Dechend, R.; Bräsen, J. H.; Müller, D. N.; Neumayer, H. H.; Budde, K. und Luft, F. C. (2002): Agonistic antibodies targeting angiotensin II type 1 receptor cause acute vascular rejection in the absence of immunological risk, Conrad, K.; Fritzler, M.; Meurer, M.; Sack, U. und Shoenfeld, Y., From proteomics to molecular epidemiology: Relevance of autoantibodies. Report on the 6^th Symposium on Autoantibodies , Seite 381-382,

[28] Fu, L. X.; Magnusson, Y.; Bergh, C. H.; Liljeqvist, J. A.; Waagstein, F.; Hjalmarson, A. und Hoebeke, J. (1993): Localization of a functional autoimmune epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy, J.Clin.Invest (Band 91), Nr. 5, Seite 1964-1968. URL:

[29] Eftekhari, P.; Salle, L.; Lezoualc'h, F.; Mialet, J.; Gastineau, M.; Briand, J. P.; Isenberg, D. A.; Fournie, G. J.; Argibay, J.; Fischmeister, R.; Muller, S. und Hoebeke, J. (2000): Anti-SSA/Ro52 autoantibodies blocking the cardiac 5-HT4 serotoninergic receptor could explain neonatal lupus congenital heart block, Eur.J.Immunol. (Band 30), Nr. 10, Seite 2782-2790. URL:

[30] Lewis, R. A.; Selwa, J. F. und Lisak, R. P. (1995): Myasthenia gravis: immunological mechanisms and immunotherapy, Ann.Neurol. (Band 37 Suppl 1:S51-62.), Seite S51-S62.

[31] Costagliola, S.; Morgenthaler, N. G.; Hoermann, R.; Badenhoop, K.; Struck, J.; Freitag, D.; Poertl, S.; Weglohner, W.; Hollidt, J. M.; Quadbeck, B.; Dumont, J. E.; Schumm-Draeger, P. M.; Bergmann, A.; Mann, K.; Vassart, G. und Usadel, K. H. (1999): Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease, J.Clin.Endocrinol.Metab (Band 84), Nr. 1, Seite 90-97. URL:

[32] (1990): Pschyrembel Klinisches Wörterbuch, 256., neu bearb. Auflage. Auflage , Walter de Gruyter & Co.,

[33] Caspary, L. und Creutzig, A. (2006): [Raynaud's phenomenon--current diagnosis and therapy], Dtsch.Med.Wochenschr. (Band 131), Nr. 21, Seite 1223-1227. URL:

[34] Doutre, M. (1999): Physiopathology of urticaria, Eur.J.Dermatol. (Band 9), Nr. 8, Seite 601-605.

[35] Furman, M. I.; Benoit, S. E.; Barnard, M. R.; Valeri, C. R.; Borbone, M. L.; Becker, R. C.; Hechtman, H. B. und Michelson, A. D. (1998): Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease, J.Am.Coll.Cardiol. (Band 31), Nr. 2, Seite 352-358.

[36] Golino, P.; Crea, F. und Willerson, J. T. (2002): How to study the effects of platelet aggregation and thrombosis on coronary vasomotion and their clinical relevance, Ital.Heart J. (Band 3), Nr. 4, Seite 220-225.

[37] Machado, A. P.; Saavedra, J. A. und Ribeiro, C. (1994): Insights into the role of thromboxane A2 and serotonin in the pathogenesis of unstable angina, Rev.Port.Cardiol. (Band 13), Nr. 12, Seite 935-46, 893.

[38] Herve, P.; Humbert, M.; Sitbon, O.; Parent, F.; Nunes, H.; Legal, C.; Garcia, G. und Simonneau, G. (2001): Pathobiology of pulmonary hypertension. The role of platelets and thrombosis, Clin.Chest Med. (Band 22), Nr. 3, Seite 451-458.

[39] Mosler, N (14-3-2007):Pulmonale Hypertonie - Neuer Wirkstoff für PAH-Therapie, Cardio News, Seite 16-16.

[40] Erdmann, E (14-3-2007):PAH-Patienten hilft, was Rauchern die Männlichkeit zurückgeben kann, Cardio News, Seite 14-14.

[41] Hoeper, M. (14-3-2007):Neue pharmakologische Therapien: Lässt sich die Transplantation bei Lungenhochdruck verhindern?, Cardio News, Seite 14-15.

[42] Altieri, D. C. und Edgington, T. S. (1990): Identification of effector cell protease receptor-1. A leukocyte-distributed receptor for the serine protease factor Xa, J.Immunol. (Band 145), Nr. 1, Seite 246-253. URL:

[43] Behrendt, N.; Ronne, E. und Dano, K. (1995): The structure and function of the urokinase receptor, a membrane protein governing plasminogen activation on the cell surface, Biol.Chem.Hoppe Seyler (Band 376), Nr. 5, Seite 269-279. URL:

[44] Dery, O.; Corvera, C. U.; Steinhoff, M. und Bunnett, N. W. (1998): Proteinase-activated receptors: novel mechanisms of signaling by serine proteases, Am.J.Physiol (Band 274), Nr. 6 Pt 1, Seite C1429-C1452. URL:

[45] Vu, T. K.; Hung, D. T.; Wheaton, V. I. und Coughlin, S. R. (1991): Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation, Cell (Band 64), Nr. 6, Seite 1057-1068. URL:

[46] Colognato, R.; Slupsky, J. R.; Jendrach, M.; Burysek, L.; Syrovets, T. und Simmet, T. (2003): Differential expression and regulation of protease-activated receptors in human peripheral monocytes and monocyte-derived antigen-presenting cells, Blood (Band 102), Nr. 7, Seite 2645-2652. URL:

[47] Li, T. und He, S. (2006): Induction of IL-6 release from human T cells by PAR-1 and PAR-2 agonists, Immunol.Cell Biol. (Band 84), Nr. 5, Seite 461-466. URL:

[48] Nystedt, S.; Emilsson, K.; Wahlestedt, C. und Sundelin, J. (1994): Molecular cloning of a potential proteinase activated receptor, Proc.Natl.Acad.Sci.U.S.A (Band 91), Nr. 20, Seite 9208-9212. URL:

[49] Belham, C. M.; Tate, R. J.; Scott, P. H.; Pemberton, A. D.; Miller, H. R.; Wadsworth, R. M.; Gould, G. W. und Plevin, R. (1996): Trypsin stimulates proteinase-activated receptor-2-dependent and -independent activation of mitogen-activated protein kinases, Biochem.J. (Band 320 ( Pt 3)), Seite 939-946. URL:

[50] Camerer, E.; Rottingen, J. A.; Iversen, J. G. und Prydz, H. (1996): Coagulation factors VII and X induce Ca2+ oscillations in Madin-Darby canine kidney cells only when proteolytically active, J.Biol.Chem. (Band 271), Nr. 46, Seite 29034-29042. URL:

[51] Mirza, H.; Schmidt, V. A.; Derian, C. K.; Jesty, J. und Bahou, W. F. (1997): Mitogenic responses mediated through the proteinase-activated receptor-2 are induced by expressed forms of mast cell a, Blood (Band 90), Nr. 10, Seite 3914-3922. URL:

[52] Molino, M.; Barnathan, E. S.; Numerof, R.; Clark, J.; Dreyer, M.; Cumashi, A.; Hoxie, J. A.; Schechter, N.; Woolkalis, M. und Brass, L. F. (1997): Interactions of mast cell tryptase with thrombin receptors and PAR-2, J.Biol.Chem. (Band 272), Nr. 7, Seite 4043-4049. URL:

[53] Bretschneider, E.; Kaufmann, R.; Braun, M.; Wittpoth, M.; Glusa, E.; Nowak, G. und Schror, K. (1999): Evidence for proteinase-activated receptor-2 (PAR-2)-mediated mitogenesis in coronary artery smooth muscle cells, Br.J.Pharmacol. (Band 126), Nr. 8, Seite 1735-1740. URL:

[54] Camerer, E.; Huang, W. und Coughlin, S. R. (2000): Tissue factor- and factor X-dependent activation of protease-activated receptor 2 by factor VIIa, Proc.Natl.Acad.Sci.U.S.A. (Band 97), Nr. 10, Seite 5255-5260.

[55] Ishihara, H.; Connolly, A. J.; Zeng, D.; Kahn, M. L.; Zheng, Y. W.; Timmons, C.; Tram, T. und Coughlin, S. R. (1997): Protease-activated receptor 3 is a second thrombin receptor in humans, Nature (Band 386), Nr. 6624, Seite 502-506. URL:

[56] Xu, W. F.; Andersen, H.; Whitmore, T. E.; Presnell, S. R.; Yee, D. P.; Ching, A.; Gilbert, T.; Davie, E. W. und Foster, D. C. (1998): Cloning and characterization of human protease-activated receptor 4, Proc.Natl.Acad.Sci.U.S.A (Band 95), Nr. 12, Seite 6642-6646. URL:

[57] Kahn, M. L.; Zheng, Y. W.; Huang, W.; Bigornia, V.; Zeng, D.; Moff, S.; Farese, R. V., Jr.; Tam, C. und Coughlin, S. R. (1998): A dual thrombin receptor system for platelet activation, Nature (Band 394), Nr. 6694, Seite 690-694. URL:

[58] Selak, M. A.; Chignard, M. und Smith, J. B. (1988): Cathepsin G is a strong platelet agonist released by neutrophils, Biochem.J. (Band 251), Nr. 1, Seite 293-299. URL:

[59] Sambrano, G. R.; Huang, W.; Faruqi, T.; Mahrus, S.; Craik, C. und Coughlin, S. R. (2000): Cathepsin G activates protease-activated receptor-4 in human platelets, J.Biol.Chem. (Band 275), Nr. 10, Seite 6819-6823. URL:

[60] Blackhart, B. D.; Emilsson, K.; Nguyen, D.; Teng, W.; Martelli, A. J.; Nystedt, S.; Sundelin, J. und Scarborough, R. M. (1996): Ligand cross-reactivity within the protease-activated receptor family, J.Biol.Chem. (Band 271), Nr. 28, Seite 16466-16471. URL:

[61] Steinberg, S. F. (2005): The cardiovascular actions of protease-activated receptors, Mol.Pharmacol. (Band 67), Nr. 1, Seite 2-11. URL:

[62] Ludeman, M. J.; Zheng, Y. W.; Ishii, K. und Coughlin, S. R. (2004): Regulated shedding of PAR1 N-terminal exodomain from endothelial cells, J.Biol.Chem. (Band 279), Nr. 18, Seite 18592-18599. URL:

[63] Molino, M.; Blanchard, N.; Belmonte, E.; Tarver, A. P.; Abrams, C.; Hoxie, J. A.; Cerletti, C. und Brass, L. F. (1995): Proteolysis of the human platelet and endothelial cell thrombin receptor by neutrophil-derived cathepsin G, J.Biol.Chem. (Band 270), Nr. 19, Seite 11168-11175. URL:

[64] Jacques, S. L. und Kuliopulos, A. (2003): Protease-activated receptor-4 uses dual prolines and an anionic retention motif for thrombin recognition and cleavage, Biochem.J. (Band 376), Nr. Pt 3, Seite 733-740. URL:

[65] Renesto, P.; Si-Tahar, M.; Moniatte, M.; Balloy, V.; Van Dorsselaer, A.; Pidard, D. und Chignard, M. (1997): Specific inhibition of thrombin-induced cell activation by the neutrophil proteinases elastase, cathepsin G, and proteinase 3: evidence for distinct cleavage sites within the aminoterminal domain of the thrombin receptor, Blood. (Band 89), Nr. 6, Seite 1944-1953.

[66] Blackhart, B. D.; Ruslim-Litrus, L.; Lu, C. C.; Alves, V. L.; Teng, W.; Scarborough, R. M.; Reynolds, E. E. und Oksenberg, D. (2000): Extracellular mutations of protease-activated receptor-1 result in differential activation by thrombin and thrombin receptor agonist peptide, Mol.Pharmacol. (Band 58), Nr. 6, Seite 1178-1187. URL:

[67] Vouret-Craviari, V.; Boquet, P.; Pouyssegur, J. und Obberghen-Schilling, E. (1998): Regulation of the actin cytoskeleton by thrombin in human endothelial cells: role of Rho proteins in endothelial barrier function, Mol.Biol.Cell (Band 9), Nr. 9, Seite 2639-2653. URL:

[68] Taylor, S. J.; Chae, H. Z.; Rhee, S. G. und Exton, J. H. (1991): Activation of the beta 1 isozyme of phospholipase C by alpha subunits of the Gq class of G proteins, Nature (Band 350), Nr. 6318, Seite 516-518. URL:

[69] Katada, T.; Bokoch, G. M.; Smigel, M. D.; Ui, M. und Gilman, A. G. (1984): The inhibitory guanine nucleotide-binding regulatory component of adenylate cyclase. Subunit dissociation and the inhibition of adenylate cyclase in S49 lymphoma cyc- and wild type membranes, J.Biol.Chem. (Band 259), Nr. 6, Seite 3586-3595. URL:

[70] Levitzki, A. und Bar-Sinai, A. (1991): The regulation of adenylyl cyclase by receptor-operated G proteins, Pharmacol.Ther. (Band 50), Nr. 3, Seite 271-283. URL:

[71] Nystedt, S.; Larsson, A. K.; Aberg, H. und Sundelin, J. (1995): The mouse proteinase-activated receptor-2 cDNA and gene. Molecular cloning and functional expression, J.Biol.Chem. (Band 270), Nr. 11, Seite 5950-5955. URL:

[72] Sabri, A.; Muske, G.; Zhang, H.; Pak, E.; Darrow, A.; Andrade-Gordon, P. und Steinberg, S. F. (2000): Signaling properties and functions of two distinct cardiomyocyte protease-activated receptors, Circ.Res. (Band 86), Nr. 10, Seite 1054-1061. URL:

[73] Schultheiss, M.; Neumcke, B. und Richter, H. P. (1997): Endogenous trypsin receptors in Xenopus oocytes: linkage to internal calcium stores, Cell Mol.Life Sci. (Band 53), Nr. 10, Seite 842-849. URL:

[74] Yu, R. und Hinkle, P. M. (1997): Desensitization of thyrotropin-releasing hormone receptor-mediated responses involves multiple steps, J.Biol.Chem. (Band 272), Nr. 45, Seite 28301-28307. URL:

[75] Macfarlane, S. R.; Seatter, M. J.; Kanke, T.; Hunter, G. D. und Plevin, R. (2001): Proteinase-activated receptors, Pharmacol.Rev. (Band 53), Nr. 2, Seite 245-282. URL:

[76] Kahn, M. L.; Nakanishi-Matsui, M.; Shapiro, M. J.; Ishihara, H. und Coughlin, S. R. (1999): Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin, J.Clin.Invest (Band 103), Nr. 6, Seite 879-887. URL:

[77] Brass, L. F.; Manning, D. R.; Cichowski, K. und Abrams, C. S. (1997): Signaling through G proteins in platelets: to the integrins and beyond, Thromb.Haemost. (Band 78), Nr. 1, Seite 581-589. URL:

[78] Hamberg, M.; Svensson, J. und Samuelsson, B. (1975): Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides, Proc.Natl.Acad.Sci.U.S.A (Band 72), Nr. 8, Seite 2994-2998. URL:

[79] Stenberg, P. E.; McEver, R. P.; Shuman, M. A.; Jacques, Y. V. und Bainton, D. F. (1985): A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation, J.Cell Biol. (Band 101), Nr. 3, Seite 880-886. URL:

[80] Hughes, P. E. und Pfaff, M. (1998): Integrin affinity modulation, Trends Cell Biol. (Band 8), Nr. 9, Seite 359-364. URL:

[81] Sims, P. J.; Wiedmer, T.; Esmon, C. T.; Weiss, H. J. und Shattil, S. J. (1989): Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity, J.Biol.Chem. (Band 264), Nr. 29, Seite 17049-17057. URL:

[82] Coughlin, S. R. (2001): Protease-activated receptors in vascular biology, Thromb.Haemost. (Band 86), Nr. 1, Seite 298-307. URL:

[83] Lum, H. und Malik, A. B. (1994): Regulation of vascular endothelial barrier function, Am.J.Physiol (Band 267), Nr. 3 Pt 1, Seite L223-L241. URL:

[84] Cirino, G.; Cicala, C.; Bucci, M. R.; Sorrentino, L.; Maraganore, J. M. und Stone, S. R. (1996): Thrombin functions as an inflammatory mediator through activation of its receptor, J.Exp.Med. (Band 183), Nr. 3, Seite 821-827. URL:

[85] Mirza, H.; Yatsula, V. und Bahou, W. F. (1996): The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells, J.Clin.Invest (Band 97), Nr. 7, Seite 1705-1714. URL:

[86] Alm, A. K.; Norstrom, E.; Sundelin, J. und Nystedt, S. (1999): Stimulation of proteinase activated receptor-2 causes endothelial cells to promote blood coagulation in vitro, Thromb.Haemost. (Band 81), Nr. 6, Seite 984-988. URL:

[87] Jerius, H.; Beall, A.; Woodrum, D.; Epstein, A. und Brophy, C. (1998): Thrombin-induced vasospasm: cellular signaling mechanisms, Surgery (Band 123), Nr. 1, Seite 46-50. URL:

[88] Vergnolle, N.; Hollenberg, M. D. und Wallace, J. L. (1999): Pro- and anti-inflammatory actions of thrombin: a distinct role for proteinase-activated receptor-1 (PAR1), Br.J.Pharmacol. (Band 126), Nr. 5, Seite 1262-1268. URL:

[89] Vergnolle, N.; Hollenberg, M. D.; Sharkey, K. A. und Wallace, J. L. (1999): Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw, Br.J.Pharmacol. (Band 127), Nr. 5, Seite 1083-1090. URL:

[90] Naldini, A. und Carney, D. H. (1996): Thrombin modulation of natural killer activity in human peripheral lymphocytes, Cell Immunol. (Band 172), Nr. 1, Seite 35-42.

[91] Naldini, A.; Sower, L.; Bocci, V.; Meyers, B. und Carney, D. H. (1998): Thrombin receptor expression and responsiveness of human monocytic cells to thrombin is linked to interferon-induced cellular differentiation, J.Cell Physiol. (Band 177), Nr. 1, Seite 76-84.

[92] Schaffner, A.; Rhyn, P.; Schoedon, G. und Schaer, D. J. (2005): Regulated expression of platelet factor 4 in human monocytes--role of PARs as a quantitatively important monocyte activation pathway, J.Leukoc.Biol. (Band 78), Nr. 1, Seite 202-209.

[93] Corvera, C. U.; Dery, O.; McConalogue, K.; Gamp, P.; Thoma, M.; Al Ani, B.; Caughey, G. H.; Hollenberg, M. D. und Bunnett, N. W. (1999): Thrombin and mast cell tryptase regulate guinea-pig myenteric neurons through proteinase-activated receptors-1 and -2, J.Physiol (Band 517 ( Pt 3)), Seite 741-756. URL:

[94] Steinhoff, M.; Vergnolle, N.; Young, S. H.; Tognetto, M.; Amadesi, S.; Ennes, H. S.; Trevisani, M.; Hollenberg, M. D.; Wallace, J. L.; Caughey, G. H.; Mitchell, S. E.; Williams, L. M.; Geppetti, P.; Mayer, E. A. und Bunnett, N. W. (2000): Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism, Nat.Med. (Band 6), Nr. 2, Seite 151-158. URL:

[95] Yanagisawa, M.; Kurihara, H.; Kimura, S.; Tomobe, Y.; Kobayashi, M.; Mitsui, Y.; Yazaki, Y.; Goto, K. und Masaki, T. (1988): A novel potent vasoconstrictor peptide produced by vascular endothelial cells, Nature (Band 332), Nr. 6163, Seite 411-415. URL:

[96] Inoue, A.; Yanagisawa, M.; Kimura, S.; Kasuya, Y.; Miyauchi, T.; Goto, K. und Masaki, T. (1989): The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes, Proc.Natl.Acad.Sci.U.S.A (Band 86), Nr. 8, Seite 2863-2867. URL:

[97] Schmidt, M.; Kroger, B.; Jacob, E.; Seulberger, H.; Subkowski, T.; Otter, R.; Meyer, T.; Schmalzing, G. und Hillen, H. (1994): Molecular characterization of human and bovine endothelin converting enzyme (ECE-1), FEBS Lett. (Band 356), Nr. 2-3, Seite 238-243. URL:

[98] Douglas, S. A. und Ohlstein, E. H. (1997): Signal transduction mechanisms mediating the vascular actions of endothelin, J.Vasc.Res. (Band 34), Nr. 3, Seite 152-164. URL:

[99] Arai, H.; Hori, S.; Aramori, I.; Ohkubo, H. und Nakanishi, S. (1990): Cloning and expression of a cDNA encoding an endothelin receptor, Nature (Band 348), Nr. 6303, Seite 730-732. URL:

[100] Sakurai, T.; Yanagisawa, M.; Takuwa, Y.; Miyazaki, H.; Kimura, S.; Goto, K. und Masaki, T. (1990): Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor, Nature (Band 348), Nr. 6303, Seite 732-735. URL:

[101] Masaki, T.; Miwa, S.; Sawamura, T.; Ninomiya, H. und Okamoto, Y. (1999): Subcellular mechanisms of endothelin action in vascular system, Eur.J.Pharmacol. (Band 375), Nr. 1-3, Seite 133-138. URL:

[102] Rubanyi, G. M. und Polokoff, M. A. (1994): Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology, Pharmacol.Rev. (Band 46), Nr. 3, Seite 325-415. URL:

[103] Sakamoto, A.; Yanagisawa, M.; Sawamura, T.; Enoki, T.; Ohtani, T.; Sakurai, T.; Nakao, K.; Toyo-oka, T. und Masaki, T. (1993): Distinct subdomains of human endothelin receptors determine their selectivity to endothelinA-selective antagonist and endothelinB-selective agonists, J.Biol.Chem. (Band 268), Nr. 12, Seite 8547-8553. URL:

[104] Orry, A. J. und Wallace, B. A. (2000): Modeling and docking the endothelin G-protein-coupled receptor, Biophys.J. (Band 79), Nr. 6, Seite 3083-3094. URL:

[105] Takigawa, M.; Sakurai, T.; Kasuya, Y.; Abe, Y.; Masaki, T. und Goto, K. (1995): Molecular identification of guanine-nucleotide-binding regulatory proteins which couple to endothelin receptors, Eur.J.Biochem. (Band 228), Nr. 1, Seite 102-108. URL:

[106] Sugden, P. H. und Clerk, A. (2005): Endothelin signalling in the cardiac myocyte and its pathophysiological relevance, Curr.Vasc.Pharmacol. (Band 3), Nr. 4, Seite 343-351. URL:

[107] Arai, K.; Maruyama, Y.; Nishida, M.; Tanabe, S.; Takagahara, S.; Kozasa, T.; Mori, Y.; Nagao, T. und Kurose, H. (2003): Differential requirement of G alpha12, G alpha13, G alphaq, and G beta gamma for endothelin-1-induced c-Jun NH2-terminal kinase and extracellular signal-regulated kinase activation, Mol.Pharmacol. (Band 63), Nr. 3, Seite 478-488. URL:

[108] Trevisi, L.; Bova, S.; Cargnelli, G.; Ceolotto, G. und Luciani, S. (2002): Endothelin-1-induced arachidonic acid release by cytosolic phospholipase A2 activation in rat vascular smooth muscle via extracellular signal-regulated kinases pathway, Biochem.Pharmacol. (Band 64), Nr. 3, Seite 425-431. URL:

[109] Wu-Wong, J. R.; Dayton, B. D. und Opgenorth, T. J. (1996): Endothelin-1-evoked arachidonic acid release: a Ca(2+)-dependent pathway, Am.J.Physiol (Band 271), Nr. 3 Pt 1, Seite C869-C877. URL:

[110] Curtis, T. M. und Scholfield, C. N. (2000): Transient Ca2+-activated Cl-currents with endothelin in isolated arteriolar smooth muscle cells of the choroid, Invest Ophthalmol.Vis.Sci. (Band 41), Nr. 8, Seite 2279-2285. URL:

[111] Masaki, T. (1995): Possible role of endothelin in endothelial regulation of vascular tone, Annu.Rev.Pharmacol.Toxicol. (Band 35), Seite 235-255. URL:

[112] Iwamuro, Y.; Miwa, S.; Zhang, X. F.; Minowa, T.; Enoki, T.; Okamoto, Y.; Hasegawa, H.; Furutani, H.; Okazawa, M.; Ishikawa, M.; Hashimoto, N. und Masaki, T. (1999): Activation of three types of voltage-independent Ca2+ channel in A7r5 cells by endothelin-1 as revealed by a novel Ca2+ channel blocker LOE 908, Br.J.Pharmacol. (Band 126), Nr. 5, Seite 1107-1114. URL:

[113] Zhang, X. F.; Iwamuro, Y.; Enoki, T.; Okazawa, M.; Lee, K.; Komuro, T.; Minowa, T.; Okamoto, Y.; Hasegawa, H.; Furutani, H.; Miwa, S. und Masaki, T. (1999): Pharmacological characterization of Ca2+ entry channels in endothelin-1-induced contraction of rat aorta using LOE 908 and SK&F 96365, Br.J.Pharmacol. (Band 127), Nr. 6, Seite 1388-1398. URL:

[114] Minowa, T.; Miwa, S.; Kobayashi, S.; Enoki, T.; Zhang, X. F.; Komuro, T.; Iwamuro, Y. und Masaki, T. (1997): Inhibitory effect of nitrovasodilators and cyclic GMP on ET-1-activated Ca(2+)-permeable nonselective cation channel in rat aortic smooth muscle cells, Br.J.Pharmacol. (Band 120), Nr. 8, Seite 1536-1544. URL:

[115] Jagroop, I. A.; Daskalopoulou, S. S. und Mikhailidis, D. P. (2005): Endothelin-1 and human platelets, Curr.Vasc.Pharmacol. (Band 3), Nr. 4, Seite 393-399.

[116] Malendowicz, L. K.; Brelinska, R.; De Caro, R.; Trejer, M. und Nussdorfer, G. G. (1998): Endothelin-1, acting via the A receptor subtype, stimulates thymocyte proliferation in the rat, Life Sci. (Band 62), Nr. 21, Seite 1959-1963.

[117] Sampaio, A. L.; Rae, G. A. und Henriques, M. M. (2000): Role of endothelins on lymphocyte accumulation in allergic pleurisy, J.Leukoc.Biol. (Band 67), Nr. 2, Seite 189-195.

[118] Guruli, G.; Pflug, B. R.; Pecher, S.; Makarenkova, V.; Shurin, M. R. und Nelson, J. B. (2004): Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops, Blood. (Band 104), Nr. 7, Seite 2107-2115.

[119] Miyauchi, T. und Masaki, T. (1999): Pathophysiology of endothelin in the cardiovascular system, Annu.Rev.Physiol (Band 61), Seite 391-415. URL:

[120] Sakai, S.; Miyauchi, T.; Kobayashi, M.; Yamaguchi, I.; Goto, K. und Sugishita, Y. (1996): Inhibition of myocardial endothelin pathway improves long-term survival in heart failure, Nature (Band 384), Nr. 6607, Seite 353-355. URL:

[121] Bousette, N. und Giaid, A. (2003): Endothelin-1 in atherosclerosis and other vasculopathies, Can.J.Physiol Pharmacol. (Band 81), Nr. 6, Seite 578-587. URL:

[122] Seiler, S. M.; Peluso, M.; Tuttle, J. G.; Pryor, K.; Klimas, C.; Matsueda, G. R. und Bernatowicz, M. S. (1996): Thrombin receptor activation by thrombin and receptor-derived peptides in platelet and CHRF-288 cell membranes: receptor-stimulated GTPase and evaluation of agonists and partial agonists, Mol.Pharmacol. (Band 49), Nr. 1, Seite 190-197.

[123] Rasmussen, U. B.; Gachet, C.; Schlesinger, Y.; Hanau, D.; Ohlmann, P.; Obberghen-Schilling, E.; Pouyssegur, J.; Cazenave, J. P. und Pavirani, A. (1993): A peptide ligand of the human thrombin receptor antagonizes alpha-thrombin and partially activates platelets, J.Biol.Chem. (Band 268), Nr. 19, Seite 14322-14328.

[124] Lehmberg, J.; Putz, C.; Furst, M.; Beck, J.; Baethmann, A. und Uhl, E. (2003): Impact of the endothelin-A receptor antagonist BQ 610 on microcirculation in global cerebral ischemia and reperfusion, Brain Res. (Band 961), Nr. 2, Seite 277-286.

[125] Wallukat, G.; Morwinski, R; Nissen, E.; Müller, J. und Luft, F. C. (2003): Effects of the tryptase receptor activating peptide and antibodies against the tryptase receptor PAR-2 on neonatal rat cardiomyocytes in culture, Matsumori, A, Cardiomyopathies and heart failure: Biomolecular, infectious and immune mechanisms , Seite 173-184, Kluwer Academic Publishers,

[126] Albrecht, S.; Luther, T.; Grossmann, H.; Flössel, C.; Kotzsch, M. und Müller, M. (1992): An ELISA for tissue factor using monoclonal antibodies, Blood Coagul.Fibrinolysis. (Band 3), Nr. 3, Seite 263-270.

[127] Wollenberger, A. (1985): Isolated heart cells as a model of the myocardium, Basic Res.Cardiol. (Band 80 Suppl 2:9-13.), Seite 9-13.

[128] Kolde, H.-J. (2001): Haemostasis, Pentapharm Ltd.,

[129] Auron, P. E. (1998): The interleukin 1 receptor: ligand interactions and signal transduction, Cytokine Growth Factor Rev. (Band 9), Nr. 3-4, Seite 221-237.

[130] Kereveur, A.; Enjyoji, K.; Masuda, K.; Yutani, C. und Kato, H. (2001): Production of tissue factor pathway inhibitor in cardiomyocytes and its upregulation by interleukin-1, Thromb.Haemost. (Band 86), Nr. 5, Seite 1314-1319.

[131] Shindo, T.; Ikeda, U.; Ohkawa, F.; Kawahara, Y.; Yokoyama, M. und Shimada, K. (1995): Nitric oxide synthesis in cardiac myocytes and fibroblasts by inflammatory cytokines, Cardiovasc.Res. (Band 29), Nr. 6, Seite 813-819.

[132] Banchereau, J. und Galizzi, J. P. (1990): Receptors for interleukin 4, interleukin 5 and interleukin 6, Ann.Ist.Super.Sanita. (Band 26), Nr. 3-4, Seite 453-467.

[133] Saito, M.; Yoshida, K.; Hibi, M.; Taga, T. und Kishimoto, T. (1992): Molecular cloning of a murine IL-6 receptor-associated signal transducer, gp130, and its regulated expression in vivo, J.Immunol. (Band 148), Nr. 12, Seite 4066-4071.

[134] Villegas, S.; Villarreal, F. J. und Dillmann, W. H. (2000): Leukemia Inhibitory Factor and Interleukin-6 downregulate sarcoplasmic reticulum Ca2+ ATPase (SERCA2) in cardiac myocytes, Basic Res.Cardiol. (Band 95), Nr. 1, Seite 47-54.

[135] Tanaka, T.; Kanda, T.; Takahashi, T.; Saegusa, S.; Moriya, J. und Kurabayashi, M. (2004): Interleukin-6-induced reciprocal expression of SERCA and natriuretic peptides mRNA in cultured rat ventricular myocytes, J.Int.Med.Res. (Band 32), Nr. 1, Seite 57-61.

[136] Smart, N.; Mojet, M. H.; Latchman, D. S.; Marber, M. S.; Duchen, M. R. und Heads, R. J. (2006): IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes, Cardiovasc.Res. (Band 69), Nr. 1, Seite 164-177.

[137] Palsson-McDermott, E. M. und O'Neill, L. A. (2004): Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4, Immunology. (Band 113), Nr. 2, Seite 153-162.

[138] Tavener, S. A. und Kubes, P. (2005): Is there a role for cardiomyocyte toll-like receptor 4 in endotoxemia?, Trends Cardiovasc.Med. (Band 15), Nr. 5, Seite 153-157.

[139] Calabro, P.; Willerson, J. T. und Yeh, E. T. (2003): Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells, Circulation. (Band 108), Nr. 16, Seite 1930-1932.

[140] Klouche, M.; Bhakdi, S.; Hemmes, M. und Rose-John, S. (1999): Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor, J.Immunol. (Band 163), Nr. 8, Seite 4583-4589.

[141] Kaur, J.; Dhaunsi, G. S. und Turner, R. B. (2004): Interleukin-1 and nitric oxide increase NADPH oxidase activity in human coronary artery smooth muscle cells, Med.Princ.Pract. (Band 13), Nr. 1, Seite 26-29.

[142] Beaumont, D. O.; Whitten, K. W.; Mock, R. G. und Slattery, C. W. (1989): Measuring platelet function with platelet shape change, an early event in aggregation, Thromb.Res. (Band 53), Nr. 2, Seite 109-127.

[143] Frishman, W. H.; Huberfeld, S.; Okin, S.; Wang, Y. H.; Kumar, A. und Shareef, B. (1995): Serotonin and serotonin antagonism in cardiovascular and non-cardiovascular disease, J.Clin.Pharmacol. (Band 35), Nr. 6, Seite 541-572.

[144] Dorsam, R. T.; Kim, S.; Jin, J. und Kunapuli, S. P. (2002): Coordinated signaling through both G12/13 and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets, J.Biol.Chem. (Band 277), Nr. 49, Seite 47588-47595.

[145] Barradas, M. A. und Mikhailidis, D. P. (1992): Serotonin, histamine and platelets in vascular disease with special reference to peripheral vascular disease, Braz.J.Med.Biol.Res. (Band 25), Nr. 11, Seite 1063-1076.

[146] Luscher, T. F. (1993): Platelet-vessel wall interaction: role of nitric oxide, prostaglandins and endothelins, Baillieres Clin.Haematol. (Band 6), Nr. 3, Seite 609-627.

[147] Tarpey, M. M.; White, C. R.; Suarez, E.; Richardson, G.; Radi, R. und Freeman, B. A. (1999): Chemiluminescent detection of oxidants in vascular tissue. Lucigenin but not coelenterazine enhances superoxide formation, Circ.Res. (Band 84), Nr. 10, Seite 1203-1211.

[148] Janiszewski, M.; Souza, H. P.; Liu, X.; Pedro, M. A.; Zweier, J. L. und Laurindo, F. R. (2002): Overestimation of NADH-driven vascular oxidase activity due to lucigenin artifacts, Free Radic.Biol.Med. (Band 32), Nr. 5, Seite 446-453.

[149] Liochev, S. I. und Fridovich, I. (1998): Lucigenin as mediator of superoxide production: revisited, Free Radic.Biol.Med. (Band 25), Nr. 8, Seite 926-928.

[150] Skatchkov, M. P.; Sperling, D.; Hink, U.; Mulsch, A.; Harrison, D. G.; Sindermann, I.; Meinertz, T. und Munzel, T. (1999): Validation of lucigenin as a chemiluminescent probe to monitor vascular superoxide as well as basal vascular nitric oxide production, Biochem.Biophys.Res.Commun. (Band %19;254), Nr. 2, Seite 319-324.

[151] Dörffel, Y.; Lätsch, C.; Stuhlmüller, B.; Schreiber, S.; Scholze, S.; Burmester, G. R. und Scholze, J. (1999): Preactivated peripheral blood monocytes in patients with essential hypertension, Hypertension. (Band 34), Nr. 1, Seite 113-117.

[152] Dörffel, Y.; Franz, S.; Pruss, A.; Neumann, G.; Rohde, W.; Burmester, G. R. und Scholze, J. (2001): Preactivated monocytes from hypertensive patients as a factor for atherosclerosis?, Atherosclerosis. (Band 157), Nr. 1, Seite 151-160.

[153] King, J. M.; Srivastava, K. D.; Stefano, G. B.; Bilfinger, T. V.; Bahou, W. F. und Magazine, H. I. (1997): Human monocyte adhesion is modulated by endothelin B receptor-coupled nitric oxide release, J.Immunol. (Band 158), Nr. 2, Seite 880-886.

[154] Browatzki, M.; Pfeiffer, C. A.; Schmidt, J. und Kranzhofer, R. (2005): Endothelin-1 induces CD40 but not IL-6 in human monocytes via the proinflammatory transcription factor NF-kappaB, Eur.J.Med.Res. (Band %20;10), Nr. 5, Seite 197-201.